DWA
RLMD icon

Dorsey Wright & Associates’s Relmada Therapeutics RLMD Stock Holding History

Dorsey Wright & Associates’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-240
Closed -$10K – 353
2020
Q2 		$10K Buy
+240
New +$10.1K ﹤0.01% 257

Other funds holding RLMD

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Dorsey Wright & Associates's RLMD Position: Q3 2020 in Review

Dorsey Wright & Associates sold out of Relmada Therapeutics (RLMD) in Q3 2020, closing a stake of 240 shares — an estimated $10K sold.

Dorsey Wright & Associates first reported a position in RLMD in Q2 2020 and held it in 1 quarter. The position peaked at $10K in Q2 2020. 72 funds tracked by Wall St. Rank hold RLMD as of Q3 2020.

  • Dorsey Wright & Associates reported no remaining Relmada Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Dorsey Wright & Associates sold 240 Relmada Therapeutics shares in Q3 2020, an estimated $10K.
  • Dorsey Wright & Associates first reported a position in Relmada Therapeutics in Q2 2020 and held it in 1 quarter.
  • Dorsey Wright & Associates's Relmada Therapeutics position peaked at $10K in Q2 2020.
  • 72 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q3 2020.

Based on Dorsey Wright & Associates's 13F filing for Q3 2020, filed 28 Oct 2020.